Vietnam - vietnameză - BỘ Y TẾ (CỤC QUẢN LÝ DƯỢC)

công ty tnhh thai nakorn patana việt nam - mebendazol 500mg - viên nén

Vietnam - vietnameză - BỘ Y TẾ (CỤC QUẢN LÝ DƯỢC)

công ty tnhh thai nakorn patana, việt nam - paracetamol 500 mg -

Vietnam - vietnameză - BỘ Y TẾ (CỤC QUẢN LÝ DƯỢC)

công ty tnhh thai nakorn patana việt nam - mỗi 5ml chứa: paracetamol 250mg - hỗn dịch - 250mg

Vietnam - vietnameză - BỘ Y TẾ (CỤC QUẢN LÝ DƯỢC)

công ty tnhh thai nakorn patana, việt nam - paracetamol 500mg, chlorpheniramin maleat 2mg, pseudoephedrin. hcl 30mg -

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

akorn - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate 0.5 mg in 1 g - clobetasol propionate cream and ointment are super-high potency corticosteroid formulations indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. use in pediatric patients under 12 years of age is not recommended. as with other highly active corticosteroids, therapy should be discontinued when control has been achieved. if no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. clobetasol propionate cream and ointment, usp, 0.05% are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

akorn - nedocromil sodium (unii: et8if4ks1t) (nedocromil - unii:0b535e0bn0) - nedocromil sodium 20 mg in 1 ml - nedocromil sodium ophthalmic solution is indicated for the treatment of itching associated with allergic conjunctivitis. nedocromil sodium ophthalmic solution is contraindicated in those patients who have shown hypersensitivity to nedocromil sodium or to any of the other ingredients.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

akorn - levocarnitine (unii: 0g389fzz9m) (levocarnitine - unii:0g389fzz9m) - levocarnitine 1 g in 10 ml - levocarnitine is indicated in the treatment of primary systemic carnitine deficiency. in the reported cases, the clinical presentation consisted of recurrent episodes of reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. associated symptoms included hypotonia, muscle weakness and failure to thrive. a diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see clinical pharmacology ). in some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. levocarnitine is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency. none known.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

oak pharmaceuticals, inc. (subsidiary of akorn, inc.) - benztropine mesylate (unii: wmj8tl7510) (benztropine - unii:1nhl2j4x8k) - benztropine mesylate 1 mg in 1 ml - for use as an adjunct in the therapy of all forms of parkinsonism (see dosage and administration). useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see precautions) due to neuroleptic drugs (e.g., phenothiazines). hypersensitivity to any component of cogentin injection. because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

akorn - lactulose (unii: 9u7d5qh5ae) (lactulose - unii:9u7d5qh5ae) - lactulose 10 g in 15 ml - for the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. controlled studies have shown that lactulose solution therapy reduced the blood ammonia levels by 25-50%; this is generally paralleled by an improvement in the patients’ mental state and by an improvement in eeg patterns. the clinical response has been observed in about 75% of the patients, which is at least as satisfactory as that resulting from neomycin therapy. an increase in patients’ protein tolerance is also frequently observed with lactulose therapy. in the treatment of chronic portal-systemic encephalopathy, lactulose has been given for over 2 years in controlled studies. since lactulose solution contains galactose (less than 1.6 g/15 ml), it is contraindicated in patients who require a low galactose diet.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

oak pharmaceuticals, inc. (subsidiary of akorn, inc.) - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride 0.5 mg in 18 ml - xylocaine (lidocaine hcl) 2% jelly is indicated for prevention and control of pain in procedures involving the male and female urethra, for topical treatment of painful urethritis, and as an anesthetic lubricant for endotracheal intubation (oral and nasal). lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of xylocaine 2% jelly.